	US 12,343,392 B2
	Compositions including Sbi adjuvants and methods of use thereof
Kyle Backman, South San Francisco, CA (US); Nikhil Dhar, Boston, MA (US); Nikolai Eroshenko, Boston, MA (US); Taylor Gill, Cambridge, MA (US); Kemo Jammeh, Brighton, MA (US); Marianna Keaveney, Walpole, MA (US); Justin Quinn, Malden, MA (US); Hannu Rajaniemi, Corte Madera, CA (US); and Everett Webster, Boston, MA (US)
Assigned to Helix Nanotechnologies Inc, Boston, MA (US)
Filed by Helix Nanotechnologies Inc., Boston, MA (US)
Filed on Aug. 18, 2023, as Appl. No. 18/235,464.
Application 18/235,464 is a division of application No. 17/685,717, filed on Mar. 3, 2022, granted, now 11,771,758.
Claims priority of provisional application 63/156,860, filed on Mar. 4, 2021.
Prior Publication US 2024/0082388 A1, Mar. 14, 2024
Int. Cl. C07K 14/47 (2006.01); A61K 39/215 (2006.01); C07K 14/11 (2006.01); C07K 14/165 (2006.01); C07K 14/31 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/215 (2013.01) [C07K 14/11 (2013.01); C07K 14/165 (2013.01); C07K 14/31 (2013.01); C07K 14/472 (2013.01); A61K 2039/575 (2013.01)]

28 Claims

1. A method comprising:

administering to a subject a composition comprising a polynucleotide encoding a fusion polypeptide;

(i) a fragment antigen, an antigen variant, or a fragment antigen variant, that comprises an epitope of a target protein antigen, and

(ii) a complement C3d-binding polypeptide from an immunoglobulin-binding protein (Sbi) of Staphylococcus aureus.